Search results
Results From The WOW.Com Content Network
Lisdexamfetamine, sold under the brand names Vyvanse and Elvanse among others, is a stimulant medication that is used to treat attention deficit hyperactivity disorder (ADHD) in children and adults and for moderate-to-severe binge eating disorder in adults. [16]
Vyvanse, Elvanse [125] Children ≥6 years & adults Children ≥6 years & adults Children ≥6 years & adults Monoamine reuptake inhibitor & releasing agent: Approved: Highly efficacious, [123] therapeutic effects are usually seen within 1–3 hours of oral administration. This is a prodrug formulation of d-amp. Methamphetamine: Desoxyn [126 ...
One study reported occurrences at regularly prescribed doses in approximately 0.1% of individuals within the first several weeks after starting amphetamine or methylphenidate therapy. [3] [4] [5] Methamphetamine psychosis, or long-term effects of stimulant use in the brain (at the molecular level), depend upon genetics and may persist for ...
In 2021, about 1.6 million people ages 12 and up in the U.S. had a methamphetamine use disorder and 1.4 million had a cocaine use disorder, according to data from the Substance Abuse and Mental ...
Vyvanse (lisdexamfetamine) – a pro-drug stimulant used to treat attention deficit hyperactivity disorder and binge eating disorder; Vyvanse is converted into Dexedrine in vivo; Viibryd – an antidepressant of the serotonin modulator and stimulators class; Vivactil (protriptyline) an antidepressant also used in the treatment of nerve pain
The Drug Enforcement Administration is increasing the production limit of Vyvanse and its generic equivalents by about 24% to address the ongoing global shortage of ADHD medications.
Exposure and response prevention (also known as exposure and ritual prevention; ERP or EX/RP) is a variant of exposure therapy that is recommended by the American Academy of Child and Adolescent Psychiatry (AACAP), the American Psychiatric Association (APA), and the Mayo Clinic as first-line treatment of OCD citing that it has the richest ...
(Reuters) -The U.S. Drug Enforcement Administration has increased the production limit for Takeda Pharmaceutical's ADHD drug Vyvanse and its generic versions by about 24% to address the ongoing ...